JIANMIN GROUP(SH:600976) Shang Hai Zheng Quan Bao·2025-12-10 18:49Group 1 - The core announcement is that Jianmin Pharmaceutical Group has received approval from the National Medical Products Administration for the oral solution of Ambroxol and Clenbuterol, which will enhance the company's product line and core competitiveness [1][2]. - The drug is indicated for the treatment of acute and chronic respiratory diseases, such as bronchitis and emphysema, and is a combination of Ambroxol hydrochloride and Clenbuterol hydrochloride [2]. - The total research and development investment for the Ambroxol oral solution has reached approximately RMB 6.514 million [3]. Group 2 - There are currently 45 companies in China that have received approval for the Ambroxol oral solution, indicating a competitive market landscape [5]. - Sales figures for the Ambroxol oral solution are projected to be RMB 666.5 million in 2023, RMB 661 million in 2024, and RMB 216 million in the first half of 2025, reflecting a significant market opportunity [5].